Search

Fibrinolysin

The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

Renzapride

It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK. … Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C).

CERE-110

CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

Artemisia vulgaris root

Artemisia vulgaris root allergenic extract is used in allergenic testing.

Laropiprant

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

Smilagenin

Pre-clinical work with smilagenin showed it to be neuroprotective against betya-amyloid and glutamate damage which contributes to Alzheimer's disease and reverses the changes in the area of the brain involved … in Parkinson’s disease.

PMI-001

It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

Dimethyl sulfone

Iofetamine I-123

ABX1100

It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978] … ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.